Synthesis and antitubercular evaluation of imidazo[2,1-b][1,3,4]thiadiazole derivatives  by Patel, Harun M. et al.
Arabian Journal of Chemistry (2017) 10, S996–S1002King Saud University
Arabian Journal of Chemistry
www.ksu.edu.sa
www.sciencedirect.comORIGINAL ARTICLESynthesis and antitubercular evaluation of
imidazo[2,1-b][1,3,4]thiadiazole derivatives* Corresponding author. Tel.: +91 9417563874; fax: +91
1881263655.
E-mail address: mnoolvi@yahoo.co.uk (M.N. Noolvi).
Peer review under responsibility of King Saud University.
Production and hosting by Elsevier
http://dx.doi.org/10.1016/j.arabjc.2013.01.001
1878-5352 ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Harun M. Patel a, Malleshappa N. Noolvi b,*, Navdeep Singh Sethi c,
Andanappa K. Gadad d, Swaranjit Singh Cameotra ea Department of Pharmaceutical Chemistry, R.C. Patel College of Pharmacy, Shirpur (Dhule) 425405, Maharshtra, India
b Department of Pharmaceutical Chemistry, Shree Dhanvantary Pharmacy College, Kim (Surat) 394110, Gujrat, India
c Department of Pharmaceutical Chemistry, ASBASJS Memorial College of Pharmacy, Bela (Ropar) 140111, Punjab, India
d School of Pharmacy, Faculty of Medical Sciences, Mount Hope, The University of the West Indies, Trinidad and Tobago
e Environmental Biotechnology & Microbial Biochemistry, Institute of Microbial Technology, Chandigarh, IndiaReceived 24 July 2012; accepted 15 January 2013
Available online 4 February 2013KEYWORDS
Imidazo[2,1-b][1,3,4]thiadia-
zole synthesis;
Mycobacterium tuberculosis;
Antitubercular activityAbstract In the present study, a series of imidazo[2,1-b][1,3,4]thiadiazole derivatives 5(a–j) were
synthesized and characterized by IR, 1H NMR, 13C NMR and mass spectral technique. The com-
pounds were evaluated for their in vitro antitubercular activity against Mycobacterium tuberculosis
H37Rv strain by using Alamar Blue susceptibility test as part of the TAACF TB screening program
under direction of the US National Institutes of Health, the NIAID division. Among the tested
compounds, 2-(1-methyl-1H-imidazol-2-yl)-6-(4-nitrophenyl)imidazo[2,1-b][1,3,4]thiadiazole (5f)
has shown the highest (98%) inhibitory activity with MIC of 3.14 lg/ml as compared to other tested
compounds. Further, some potent compounds were also assessed for their cytotoxic activity against
a mammalian Vero cell line using MTT assay. The results reveal that these compounds exhibit anti-
tubercular activity at non-cytotoxic concentrations.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Tuberculosis (TB) is the oldest documented infectious disease.
It is a chronic necrotizing bacterial infection with a wide vari-ety of manifestations caused by Mycobacterium tuberculosis,
which has plagued humans throughout recorded and archeo-
logical history (Dutt and Stead, 1999), as per the recent report
it has been estimated that approximately one-third of the
world’s population is infected with this microorganism. Today,
TB is among the top ﬁve causes of global mortality, according
to the World Health Organization (WHO) facts sheets, TB
kills 2 million people each year. It is estimated that between
2000 and 2020, nearly one billion people will be newly infected
if control is not further strengthened (Maher and Floyd, 2002;
Dye, 2002). The treatment of mycobacterial infections espe-
cially the tuberculosis, has become an important problem
due to the emergence of monodrug and multidrug-resistant
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is a need for new drugs of new structural classes and with a no-
vel mechanism of action other than isoniazid (INH), rifampi-
cin (RIF) and pyridazinamide (PZA). In this regard, no new
class of antituberculosis agents has been developed since the
introduction of rifampin into clinical in 1960s. Therefore, there
is an urgent need for the development of innovative anti-TB
agents to effectively combat TB, with improved properties
such as enhanced activity against MDR strains, reduced toxic-
ity and shortened duration of therapy. From the mid-1990s,
this infectious disease was the focus of renewed scientiﬁc inter-
est. In the last 10 years, the research on M. tuberculosis has
undergone much progress. The thriving accomplishment of
the genome of M. tuberculosis has offered a promise of a
new generation of potent drugs to combat the emerging epi-
demic of TB. The emphasis of mycobacterial research now
has shifted from gene hunting to interpretation of the biology
of the whole organism in an effort to better deﬁne which activ-
ities are likely to be critical to survival and thus amenable to
the development of new drugs (Cole et al., 1998; Barry et al.,
2000). In this regard, there have been few additions of someFigure 1 Reported and proposed anti-tubercular imidazo[2,1-b][1,3,promising new anti-tuberculosis agents, such as the long acting
rifamycins, ﬂuoroquinolones, oxazolidinones and nitroimidaz-
opyrans to the existing main-line drugs (Ian, 2001).
Imidazoles certainly belong among the most important, sig-
niﬁcant and abundant ﬁve membered heterocycles, which are
constituents of a variety of natural and synthetic products.
The advent of sulfur drugs and the later discovery of mesoionic
compounds greatly accelerated the rate of progress in the ﬁeld
of thiadiazoles. The thiadiazole and imidazole compounds are
extensively studied due to their wide spectrum of bioactivities.
Among them the imidazo(2,1-b)-1,3,4-thiadiazole derivatives
are pharmacologically important because of their immuno-
stimulant, anti-inﬂammatory, analgesic, antifungal, antimicro-
bial, antileishmanial, antitumor, anti-tuberculosis and other
activities (Mazzone et al., 1984; Srivastava and Pathak, 1991;
Gadad et al., 1999; Terzioglu and Aysel, 2003; Jaquith et al.,
2010). In addition, the reports of (Kolavi et al., 2006; Gadad
et al., 2004) on the synthesis, antimicrobial and anti-tubercular
activity of a series of 2,5,6-trisubstituted imidazo(2,1-b)-1,3,4-
thiadiazoles and 2,6-disubstituted imidazo(2,1-b)-1,3,4-thiadi-
azole derivatives respectively, which have exhibited moderate4]thiadiazole derivatives (Gadad et al., 2004; Kolavi et al., 2006).
Scheme 1 Reagents and conditions: (a) 4-N,N-Dimethylamiopyridine, DMF, Cyanogen bromide, stirred 15 h; (b) thiosemicarbazide,
triﬂuoroacetic acid, reﬂux 15 h and (c) reﬂuxed in dry ethanol for 18 h.
S998 H.M. Patel et al.to excellent anti-tuberculosis activity, are the driving force for
selecting imidazo(2,1-b)-1,3,4-thiadiazole nucleus Fig. 1.
Therefore, in view of the above facts and in continuation of
our search for newer antimycobacterial agents (Gadad et al.,
2004), in this paper we report synthesis, spectral studies, anti-
mycobacterial evaluation and cytotoxic activity of various imi-
dazo[2,1-b][1,3,4]thiadiazole derivatives.
2. Chemistry
The synthesis of 2-(1-methyl-1H-imidazol-2-yl)-6-(N-substi-
tuted phenyl)-imidazo[2,1-b][1,3,4] thiadiazole derivatives
5(a–j), denominated as imidazo[2,1-b][1,3,4]thiadiazole deriva-
tives was achieved through a versatile and efﬁcient synthetic
route outlined in Scheme 1. The starting compound 1-
methyl-1H-imidazole-2-carbonitrile 2 was prepared by stirring
cyanogen bromide and 4-N,N-dimethylamiopyridine with 1-
methyl-1H-imidazole 1 under argon gas at room temperature
(Remers et al., 1971). Compound 2 was converted into
5-(1-methyl-1H-imidazo-2-yl)-1,3,4-thiadiazol-2-amine 3 by
direct cyclization of thiosemicarbazide (Chauviere et al.,
2003). The imidazo[2,1-b][1,3,4]thiadiazole derivatives 5(a–j)
were prepared from a-bromoarylketone 4(a–j), by reaction
with 5-(1-methyl-1H-imidazo-2-yl)-1,3,4-thiadiazol-2-amine 3
under reﬂux in dry ethanol.3. Biological activity
3.1. Antimycobacterial activity
All the compounds were evaluated for in vitro antituberculosis
activity against M. tuberculosis, as part of the TAACF TB
screening program under direction of the US National Insti-
tutes of Health, the NIAID division. Rifampicin was used as
a reference drug. MIC of compounds 5(a–j) was determined
againstM. tuberculosis H37Rv (ATTCC 27294) strain by using
broth dilution assay method, the Microplate Alamar Blue
Assay (MABA) (Suling et al., 2000; Yajko et al., 1995).Compounds exhibiting ﬂuorescence were tested in the BAC-
TEC 460 radiometric system. Compounds effecting <90%
inhibition in the primary screening (MIC >6.25 lg/ml) were
not generally evaluated further. The active compounds were
re-tested by serial dilution beginning at the concentration of
6.25 lg/ml against M. tuberculosis H37Rv to determine the ac-
tual minimum inhibitory concentration (MIC) in the BACTEC
12B medium. Rifampicin was used as a reference drug. The
MIC is deﬁned as the lowest concentration affecting a reduc-
tion in ﬂuorescence of 90% relative to controls (Collins and
Franzblau, 1997). The activity data of compounds 5(a–j) are
given in Table 1.
3.2. Cytotoxicity
The cellular conversion of MTT [3-(4,5-dimethylthiazo-2-yl)-
2,5-diphenyl-tetrazolium bromide] into a formazan product
(Mosmann, 1983) was used to evaluate the cytotoxic activity
(IC50) of some selected compounds 5a–d, 5f and 5i against a
mammalian Vero cell line from the kidney of African green
monkey, organism Cercopethicus aethiops, using the Promega
Cell Titer 96 non-radioactive cell proliferation assay (Gunder-
sen et al., 2002) followed by the determination of selectivity in-
dex (SI), (IC50/MIC). The results were expressed in lM, but
for the determination of SI (selectivity index), these values
were converted into lg/mL. Compounds having high SI are
categorized as non-toxic agents (Sriram et al., 2006). MTT
[(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetra sodium bro-
mide)] is a pale yellow substrate that is cleaved by living cells
to yield a dark blue formazan product. This process requires
active mitochondria, and even freshly dead cells do not cleave
a signiﬁcant amount of MTT. Thus, the amount of MTT
cleaved is directly proportional to the number of viable cells
present, which is quantiﬁed by colorimetric methods. This as-
say was performed at IMTECH Chandigarh, India using the
standard operating procedures. The test compounds were dis-
solved in DMSO and serially diluted with complete medium to
get the range of test concentration. DMSO concentration was
kept at h 0.1% in all the test compounds. Cell lines
Table 1 In vitro antitubercular activity and cytotoxicity of compounds 5 (a–j)
.
Compound R Inhibition (%) Activity MIC (lg/ml) IC50
a SIb
5a 3-Nitro 91 + 4.34 10.56 2.43
5b 4-Bromo 94 + 5.78 11.4 1.97
5c 4-Chloro 95 + 5.48 12.3 2.24
5d 4-Fluoro 90 + 4.86 8.5 1.74
5e H 16  >6.25 – –
5f 4-Nitro 98 + 3.14 9.8 3.12
5g 4-Methyl 18  >6.25 – –
5h 3-Methyl 30  >6.25 – –
5i 2,4-Dichloro 92 + 5.66 10.3 1.81
5j 2,4-Dihydroxy 35  >6.25 – –
MIC rifampicin: 0.125–0.25 lg mL1.
SI (selectivity index) rifampicin >10.
a IC50 inhibition concentration (inhibited 50% of total cells in lM and converted into lg/mL for SI calculation).
b SI selectivity index (ratio between IC50 and M. tuberculosis MIC value).
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plates and treated with different concentrations of the test
samples and incubated at 37 C, 5% CO2 for 96 h. MTT re-
agent was added to the wells and incubated for 4 h; the dark
blue formazan product formed by the cells was dissolved in
DMSO in a safety cabinet and read at 550 nm. Percentage
inhibitions were calculated and plotted with the concentrations
and used to calculate the IC50 values in micromoles (Sriram
et al., 2006). The results of cytotoxicity studies are depicted
in Table 1.
4. Structure activity relationship (SAR)
In this study a new series of imidazo[2,1-b][1,3,4]thiadiazole
derivatives 5(a–j) derivatives were synthesized and evaluated
against M. tuberculosis, as part of the TAACF TB screening
program under direction of the US National Institutes of
Health, the NIAID division. From the ten compounds tested
5(a–j), six (5a, 5b, 5c, 5d, 5f and 5i) displayed signiﬁcant inhi-
bition effects in the primary screening against M. tuberculosis
H37Rv in the BACTEC 12B medium, using the BACTEC
460 radiometric system. Compounds demonstrating at least
90% inhibition in the primary screening were re-tested in order
to determine the actual minimum inhibitory concentration
(MIC) against M. tuberculosis.
A brief investigation of the structure–activity reveal that the
activity is considerably affected by various substituents at the
6th position of imidazo(2,1-b)-1,3,4-thiadiazole nucleus. It
has been observed that among the series, the compounds 5a,
5b, 5c, 5d, 5f, and 5i having electron withdrawing group at
the 6th position of imidazo(2,1-b)-1,3,4-thiadiazole ring exhib-
ited the signiﬁcant anti-tubercular activity while other com-
pounds showed poor to moderate activity. Among the
electron withdrawing groups, Nitro substituent (5f) at para po-sition shows an enhanced anti-tubercular activity with MIC of
3.14 lg mL1. On the other hand electron donating substitu-
ents (5g and 5h) and unsubstituted (5e) compounds resulted
in poor anti-tubercular activity.5. Result and discussion
5.1. Spectral study
A series of imidazo[2,1-b][1,3,4]thiadiazole derivatives 5(a–j)
were synthesized in good yields using the synthetic route out-
lined in Scheme 1. The starting material 5-(1-methyl-1H-imida-
zol-2-yl)-1,3,4-thiadiazol-2-amine 3 was synthesized by
reﬂuxing 1-methyl-1H-imidazole-2-carbonitrile 2 and thiosem-
icarbazide in triﬂuoroacetic acid at 60 C for 15 h. This
5-(1-methyl-1H-imidazol-2-yl)-1,3,4-thiadiazol-2-amine 3 was
further reﬂuxed with various substituted a-bromoarylketone
4(a–j) in dry ethanol for 18 h to get imidazo[2,1-b][1,3,4]thiadi-
azole 5(a–j). Structures of the synthesized compounds were
established on the basis of IR, 1H NMR, 13C NMR and mass
spectral data.
The IR spectrum of 5-(1-methyl-1H-imidazol-2-yl)-1,3,4-
thiadiazol-2-amine 3 showed a broad absorption band at
3302 cm1 for –NH2 group attached to the thiadiazole ring.
This was further characterized by 1H NMR spectral data.
The broad singlet peak at d 4.00 ppm showed the presence of
amino group. Further it was observed that the peak at d
3.96 ppm showed the presence of –CH3 group. The peak at d
6.99 and 7.13 ppm showed the presence of aromatic protons
of imidazole ring. In 13C NMR for the representative 3 we
have observed a signal that appeared at d 34.7 ppm for methyl
carbon peak. The formation of imidazo[2,1-b][1,3,4]thiadiazole
derivatives 5(a–j) was conﬁrmed by the absence of NH2 band
S1000 H.M. Patel et al.in the IR spectra and the presence of imidazole proton (C5–H)
around d 8.00 ppm and a characteristic singlet at d 3.00 ppm
for NCH3 in
1H NMR spectra. In 13C NMR for the represen-
tative 5(a–j) we have observed most characteristic signals
which appeared at around d 168–110 ppm for aromatic car-
bons and around d 29.00 ppm for methyl carbon peak. The
mass spectra showed an accurate molecular ion peak data
for the respective compounds.
5.2. Anti-tubercular activity
All the synthesized compounds 5(a–j) were evaluated for
in vitro anti-tubercular activity against M. tuberculosis strain
H37Rv by using the MABA method. The result of anti-tuber-
cular activity is presented in Table 1. All the synthesized com-
pounds exhibited an interesting activity proﬁle against the
tested mycobacterial strain. It is observed that the activity is
considerably affected by various substituents at the 6th posi-
tion of imidazo(2,1-b)-1,3,4-thiadiazole nucleus. Among the
imidazo[2,1-b][1,3,4]thiadiazole series the compounds 5a, 5b,
5c, 5d, 5f and 5i exhibited signiﬁcant antitubercular activities
but not as good as that of the nitro phenyl substituent 5f hav-
ing MIC of 3.14 lg mL1 as shown in Table 1.
5.3. Cytotoxic activity
Some selected compounds 5a, 5b, 5c, 5d, 5f and 5i were further
examined for toxicity (IC50) in a mammalian Vero cell line.
After 72 h of exposure, viability was assessed on the basis of
cellular conversion of MTT into a formazan product using
the Promega Cell Titer 96 non-radioactive cell proliferation as-
say and results are summarized in Table 1. The tested com-
pounds showed IC50 values ranging from 8.5 to 12.3 lg/mL.
Among the test compounds, 4-nitro phenyl derivative 5f
showed inferior toxicity with IC50 values of 9.8 lg/mL
(SI = 3.2). A comparison of the substitution pattern at the
6th position of imidazo(2,1-b)-1,3,4-thiadiazole nucleus dem-
onstrated that 4-ﬂuro, 4-chloro, 4-bromo and 2,4-dichloro
substituted analogs were more cytotoxic than the 4-nitro
substituted analogs. These results are important as these com-
pounds with their increased cytoliability are much attractive in
the development of new chemical entities for the treatment of
TB. This is primarily due to the fact that the eradication of TB
requires a lengthy course of treatment, and the need for an
agent with a high margin of safety becomes a primary concern.
6. Conclusion
In the present paper, we reported the synthesis and anti-tuber-
cular activity of a novel series of imidazo-[2,1-b]-1,3,4-thiadiaz-
oles. The preliminary in vitro anti-tubercular activities of these
novel series indicate that the presence of phenyl halides at C-6
position of imidazo[2,1-b][1,3,4]thiadiazoles (5a, 5b, 5c, 5d, 5f
and 5i) exhibited signiﬁcant antitubercular activities but not
as good as that of the nitro phenyl substituent 5f having
MIC of 3.14 lg mL1. Further, some selected compounds were
also assessed for their cytotoxic activity (IC50) against a mam-
malian Vero cell line using the MTT assay. The results indi-
cated that these compounds exhibit anti-tubercular activity
at non-cytotoxic concentrations. The preliminary in vitro anti-
tuberculosis screening result of novel imidazo[2,1-b][1,3,4]thia-diazole derivatives reported in the present article evidenced
that many of the compounds from the series have emerged
as potent antitubercular agents endowed with moderate to
good activity. The possible improvements in the activity can
be further achieved by a slight modiﬁcation in the substituent
on the basic imidazo[2,1-b][1,3,4]thiadiazole nucleus. Our ﬁnd-
ings will have an impact on researcher for further investigation
in this ﬁeld in search of potent antitubercular agents.
7. Experimental
All chemicals and solvents were supplied by Merck, S.D. Fine
Chemical Limited, Mumbai. All the solvents were distilled and
dried before use. The reactions were monitored with the help
of thin-layer chromatography using pre-coated aluminum
sheets with GF254 silica gel, 0.2 mm layer thickness (E. Merck).
Melting points of the synthesized compounds were recorded
on the Veego (VMP-MP) melting point apparatus. IR spec-
trum was acquired on a Shimadzu Infra Red Spectrometer,
(model FTIR-8400S). Both 1H NMR (DMSO) and 13C
NMR (DMSO) spectra of the synthesized compounds were
performed with a Bruker Avance-II 400 NMR Spectrometer
operating at 400 MHz in SAIF, Punjab University (Chandi-
garh). Chemical shifts were measured relative to internal stan-
dard TMS (d: 0). Chemical shifts are reported in d scale (ppm).
Mass spectra of the synthesized compounds were recorded at
MAT 120 in SAIF, Punjab University.
7.1. Preparation of 1-methyl-1H-imidazole-2-carbonitrile (2)
This compound is prepared as per the method given by (Re-
mers et al., 1971).
7.2. Preparation of 5-(1-methyl-1H-imidazol-2-yl)-1,3,4-thiadi-
azol-2-amine (3)
This compound is prepared as per the method given by (Chau-
viere et al., 2003).
7.3. General procedure for the synthesis of 2-(1-methyl-1H-
imidazol-2-yl)-6-(substituted phenyl)-imidazo[2,1-b][1,3,4]-
thiadiazole 5(a–j)
A mixture of equimolar quantities of 5-(1-methyl-1H-imidazo-
2-yl)-1,3,4-thiadiazol-2-amine (3) and a-bromoarylketone 4(a–
j) was reﬂuxed in dry ethanol for 18 h the excess of solvent was
distilled off and the solid hydrobromide salt that separated was
collected by ﬁltration, suspended in water and neutralized by
aqueous sodium carbonate solution to get free base 5(a–j). It
was ﬁltered, washed with water, dried and recrystallized from
ethanol.7.3.1. 2-(1-methyl-1H-imidazol-2-yl)-6-(3-nitrophenyl)imidazo-
[2,1-b][1,3,4]-thiadiazole (5a)
45% yield; mp 302–305 C; IR (KBr) mmax: 3121 (Arom.CH
strech), 2931 (Alip.CH strech), 1521 (C‚C), 1421 (CH bend),
1348, 1552 (NO2) cm
1. 1H NMR (CDCl3) d: 3.63 (s, 3H,
NCH3), 6.90–8.32 (m, 7H, Ar–H and Imidazole-H), 8.46 (s,
1H, H5-imidazole) ppm; 13C NMR (CDCl3) d: 146.4, 134.9,
133.6, 132.6, 124.9, 125.7 (3-nitro phenyl), 168.6, 142.4,
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111.4, 110.7, 29.8 (1-methyl-1H-imidazole) ppm; HRMS (EI)
m/z calcd for C14H10N6O2S: 326.0586; found: 326.0590.
7.3.2. 2-(1-methyl-1H-imidazol-2-yl)-6-(4-bromophenyl)imidazo-
[2,1-b][1,3,4]-thiadiazole (5b)
48% yield; mp 320–324 C; IR (KBr) mmax: 3129 (Arom.CH
strech), 2968 (Alip.CH strech), 1562 (C‚C), 1402 (CH bend),
621 (C–Br) cm1. 1H NMR (CDCl3) d: 3.60 (s, 3H, NCH3),
6.34–8.01 (m, 7H, Ar–H and Imidazole-H), 8.32 (s, 1H, H5-
imidazole) ppm; 13C NMR (CDCl3) d: 134.8, 132.6, 129.4,
124.6 (3-bromo phenyl), 168.8, 143.6, 138.3, 121.6 (imi-
dazo[2,1-b][1,3,4]-thiadiazole), 133.6, 122.8, 110.8, 110.7, 29.8
(1-methyl-1H-imidazole) ppm; HRMS (EI) m/z calcd for
C14H10BrN5S: 358.9840; found: 358.9845.
7.3.3. 2-(1-methyl-1H-imidazol-2-yl)-6-(4-chlorophenyl)imidazo-
[2,1-b][1,3,4]-thiadiazole (5c)
53% yield; mp 292–294 C; IR (KBr) mmax: 3101 (Arom.CH
strech), 2908 (Alip.CH strech), 1542 (C‚C), 1434 (CH bend),
721 (C–Cl) cm1. 1H NMR (CDCl3) d: 3.58 (s, 3H, NCH3),
6.21–7.99 (m, 7H, Ar–H and Imidazole-H), 8.18 (s, 1H, H5-
imidazole) ppm; 13C NMR (CDCl3) d: 136.8, 132.6, 130.7,
128.4 (4-chloro phenyl), 168.8, 141.2, 136.6, 122.7 (imi-
dazo[2,1-b][1,3,4]-thiadiazole), 133.6, 122.5, 111.8, 110.6, 29.8
(1-methyl-1H-imidazole) ppm; HRMS (EI) m/z calcd for
C14H10ClN5S: 315.0345; found: 315.0349.
7.3.4. 2-(1-methyl-1H-imidazol-2-yl)-6-(4-ﬂuorophenyl)imidazo-
[2,1-b][1,3,4]-thiadiazole (5d)
52% yield; mp 280–284 C; IR (KBr) mmax: 3110 (Arom.CH
strech), 2974 (Alip.CH strech), 1524 (C‚C), 1380 (CH bend),
1128 (C–F) cm1; 1H NMR (CDCl3) d: 3.59 (s, 3H, NCH3),
6.28–8.09 (m, 7H, Ar–H and Imidazole-H), 8.12 (s, 1H, H5-
imidazole) ppm; 13C NMR (CDCl3) d: 160.4, 130.6, 128.4,
118.0 (4-ﬂuro phenyl), 168.6, 140.8, 138.5, 120.4 (imi-
dazo[2,1-b][1,3,4]-thiadiazole), 134.4, 124.4, 110.4, 110.0, 29.8
(1-methyl-1H-imidazole) ppm; HRMS (EI) m/z calcd for
C14H10FN5S: 299.0641; found: 299.0646.
7.3.5. 2-(1-methyl-1H-imidazol-2-yl)-6-(2-hydroxyphenyl)imidazo-
[2,1-b][1,3,4]-thiadiazole (5e)
55% yield; mp 288–291 C; IR (KBr) mmax: 3430 (OH strech),
3121 (Arom.CH strech), 2942 (Alip.CH strech), 1539
(C‚C), 1395 (CH bend) cm1; 1H NMR (CDCl3) d: 3.62 (s,
3H, NCH3), 6.52–7.82 (m, 7H, Ar–H and Imidazole-H),
10.12 (s, 1H, OH) ppm; 13C NMR (CDCl3) d: 156.8, 132.6,
130.4, 122.6, 120.4, 116.4, (2-hydroxy phenyl), 168.8, 141.6,
138.5, 122.8 (imidazo[2,1-b][1,3,4]-thiadiazole), 133.8, 124.2,
110.6, 110.2, 29.8 (1-methyl-1H-imidazole) ppm. HRMS (EI)
m/z calcd for C14H11N5OS: 297.0684; found: 297.06889.7.3.6. 2-(1-methyl-1H-imidazol-2-yl)-6-(4-nitrophenyl)imidazo-
[2,1-b][1,3,4]-thiadiazole (5f)
50% yield; mp 310–312 C; IR (KBr) mmax: 3179 (Arom.CH
strech), 2936 (Alip.CH strech), 1542 (C‚C), 1381 (CH bend),
1352, 1548 (NO2) cm
1; 1H NMR (CDCl3) d: 3.63 (s, 3H,
NCH3), 6.54–7.98 (m, 7H, Ar–H and Imidazole-H), 8.24 (s,
1H, H5-imidazole) ppm; 13C NMR (CDCl3) d: 148.6, 140.6,
128.6, 126.2, (4-nitro phenyl), 168.6, 142.6, 136.6, 122.4 (imi-dazo[2,1-b][1,3,4]-thiadiazole), 136.4, 124.2, 112.8, 110.4, 29.8
(1-methyl-1H-imidazole) ppm; HRMS (EI) m/z calcd for
C14H10N6O2S: 326.0586; found: 326.0590.
7.3.7. 2-(1-methyl-1H-imidazol-2-yl)-6-(4-methylphenyl)imidazo-
[2,1-b][1,3,4]-thiadiazole (5g)
42% yield; mp 316–318 C; IR (KBr) mmax: 3038 (Arom.CH
strech), 2909 (Alip.CH strech), 1538 (C‚C), 1420 (CH bend)
cm1; 1H NMR (CDCl3) d: 3.65 (s, 3H, NCH3), 2.42 (s,3H,
CH3), 6.68–8.21 (m, 7H, Ar–H and Imidazole-H), 8.32 (s,
1H, H5-imidazole) ppm; 13C NMR (CDCl3) d: 132.4, 132.4,
130.4, 126.2, 22.6 (4-methyl phenyl), 168.6, 140.4, 138.4,
122.6 (imidazo[2,1-b][1,3,4]-thiadiazole), 134.4, 122.4, 111.6,
110.5, 29.8 (1-methyl-1H-imidazole) ppm; HRMS (EI) m/z
calcd for C15H13N5S: 295.0892; found: 295.0896.
7.3.8. 2-(1-methyl-1H-imidazol-2-yl)-6-(3-hydroxyphenyl)imidazo-
[2,1-b][1,3,4]-thiadiazole (5h)
58% yield; mp 262–264 C; IR (KBr) mmax: 3401 (OH strech),
3098 (Arom.CH strech), 2934 (Alip.CH strech), 1568
(C‚C), 1424 (CH bend) cm1; 1H NMR (CDCl3) d: 3.38 (s,
3H, NCH3), 6.64–8.18 (m, 7H, Ar–H and Imidazole-H), 8.28
(s, 1H, H5-imidazole), 10.42 (S,1H, OH) ppm; 13C NMR
(CDCl3) d: 158.4, 134.8, 132.4, 120.2, 116.4, 116.8 (3-OH phe-
nyl), 168.2, 142.4, 138.4, 122.6 (imidazo[2,1-b][1,3,4]-thiadia-
zole), 133.3, 124.8, 112.8, 110.4, 29.8 (1-methyl-1H-
imidazole) ppm; HRMS (EI) m/z calcd for C14H11N5OS:
297.0684; found: 297.0688.
7.3.9. 2-(1-methyl-1H-imidazol-2-yl)-6-(2,4-dichlorophenyl)-
imidazo[2,1-b][1,3,4]-thiadiazole (5i)
56% yield; mp 276–278 C; IR (KBr) mmax: 3078 (Arom.CH
strech), 2981 (Alip.CH strech), 1591 (C‚C), 1448 (CH bend),
721 (C–Cl) cm1; 1H NMR (CDCl3) d: 3.45 (s, 3H, NCH3),
6.42–8.05 (m, 6H, Ar–H and Imidazole-H), 8.10 (s, 1H, H5-
imidazole) ppm; 13C NMR (CDCl3) d: 136.6, 134.2, 132.6,
130.4, 128.4, 126.2 (2,4-dichloro phenyl), 168.6, 142.4, 136.4,
124.8 (imidazo[2,1-b][1,3,4]-thiadiazole), 133.2, 123.6, 111.6,
110.6, 29.6 (1-methyl-1H-imidazole) ppm. HRMS (EI) m/z
calcd for C14H9Cl2N5S: 348.9956; found: 348.9960.
7.3.10. 2-(1-methyl-1H-imidazol-2-yl)-6-(2,4-dihydroxyphenyl)-
imidazo[2,1-b][1,3,4]-thiadiazole (5j)
54% yield; mp 256–258 C; IR (KBr) mmax: 3421 (OH strech),
3048 (Arom.CH strech), 2978 (Alip.CH strech), 1571
(C‚C), 1408 (CH bend) cm1; 1H NMR (CDCl3) d: 3.51 (s,
3H, NCH3), 6.64–8.14 (m, 6H, Ar–H and Imidazole-H), 8.30
(s, 1H, H5-imidazole), 9.82 (s, 2H, OH) ppm; 13C NMR
(CDCl3) d: 160.6, 156.8, 134.2, 114.8, 112.8, 111.8 (2,4-dihy-
droxy phenyl), 168.8, 142.1, 138.8, 124.63(imidazo[2,1-
b][1,3,4]-thiadiazole), 134.8, 124.6, 112.6, 112.8, 29.8 (1-
methyl-1H-imidazole) ppm; HRMS (EI) m/z calcd for
C14H11N5O2S: 313.0633; found: 313.0638.Acknowledgements
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